{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T12:49:05Z","timestamp":1793969345692,"version":"4.8.0"},"reference-count":30,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T00:00:00Z","timestamp":1744761600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bjui-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["BJU International"],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To evaluate the impact of treatment for localised muscle\u2010invasive bladder cancer (MIBC) during the first 2\u2009years after diagnosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods<\/jats:title>\n                    <jats:p>A prospective cohort study was conducted including patients diagnosed with non\u2010metastatic (cM0) MIBC between November 2017 and November 2019 in the Netherlands. Health\u2010related quality of life (HRQoL) was measured using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ\u2010C30) as well as the MIBC\u2010specific QLQ\u2010BLM30 module. Questionnaires were administered at baseline (pre\u2010treatment) and at 6, 12 and 24\u2009months after diagnosis. Patients were grouped by treatment: neoadjuvant chemotherapy (NAC) and radical cystectomy (RC), upfront RC, chemoradiation, and radiotherapy. Linear mixed models were used to assess HRQoL changes over time per treatment group.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 518 patients participated in quality of life measurements (46% response rate). After excluding 14 patients who did not complete the EORTC QLQ\u2010C30 and 114 for baseline completion after start of treatment, a total of 390 patients were included of whom 105 underwent NAC and RC, 148 underwent upfront RC, 58 underwent chemoradiation, and 79 underwent radiotherapy alone. Over time, clinically relevant improvements in emotional functioning and future perspective were observed across all treatment groups. However, a temporary worsening in physical functioning was observed at 6\u2009months. Patients treated with RC (with or without NAC) experienced persistent deteriorations in body image and sexual functioning up to at least 2\u2009years after diagnosis, although urostomy\u2010related outcomes improved. Patients undergoing chemoradiation showed improvements in urinary symptoms, while those receiving radiotherapy reported significant worsening of dyspnoea over time.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In this largest population\u2010based study to date on HRQoL in MIBC, HRQoL largely recovered to baseline levels during the first 2\u2009years after diagnosis. However, persistent deteriorations in physical and cognitive functioning, body image, and sexual function were observed, particularly in patients treated with RC (with or without NAC).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/bju.16736","type":"journal-article","created":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T02:57:06Z","timestamp":1744858626000},"page":"657-668","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["The impact of treatment for muscle\u2010invasive bladder cancer on health\u2010related quality of life"],"prefix":"10.1111","volume":"136","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0425-6479","authenticated-orcid":false,"given":"Siberyn T.","family":"Nuijens","sequence":"first","affiliation":[{"name":"Department of Urology Radboud University Medical Center  Nijmegen The Netherlands"},{"name":"Department of Research and Development Netherlands Comprehensive Cancer Organisation  Utrecht The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0987-1342","authenticated-orcid":false,"given":"Lisa M.C.","family":"van Hoogstraten","sequence":"additional","affiliation":[{"name":"Department of Urology Radboud University Medical Center  Nijmegen The Netherlands"},{"name":"Department of Research and Development Netherlands Comprehensive Cancer Organisation  Utrecht The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"No\u00eblle B.","family":"Terpstra","sequence":"additional","affiliation":[{"name":"IQ Health Science Department Radboud University Medical Center  Nijmegen The Netherlands"},{"name":"Department of Research and Development Netherlands Comprehensive Cancer Organisation  Utrecht The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8424-7638","authenticated-orcid":false,"given":"Ivy","family":"Beeren","sequence":"additional","affiliation":[{"name":"IQ Health Science Department Radboud University Medical Center  Nijmegen The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8178-2125","authenticated-orcid":false,"given":"Alina","family":"Vrieling","sequence":"additional","affiliation":[{"name":"IQ Health Science Department Radboud University Medical Center  Nijmegen The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eveline M.","family":"Wijnen","sequence":"additional","affiliation":[{"name":"Department of Research and Development Netherlands Comprehensive Cancer Organisation  Utrecht The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard P.","family":"Meijer","sequence":"additional","affiliation":[{"name":"Department of Oncological Urology University Medical Center Utrecht  Utrecht The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lambertus A.","family":"Kiemeney","sequence":"additional","affiliation":[{"name":"Department of Urology Radboud University Medical Center  Nijmegen The Netherlands"},{"name":"IQ Health Science Department Radboud University Medical Center  Nijmegen The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Alfred","family":"Witjes","sequence":"additional","affiliation":[{"name":"Department of Urology Radboud University Medical Center  Nijmegen The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja K.H.","family":"Aben","sequence":"additional","affiliation":[{"name":"IQ Health Science Department Radboud University Medical Center  Nijmegen The Netherlands"},{"name":"Department of Research and Development Netherlands Comprehensive Cancer Organisation  Utrecht The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,4,16]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2020.03.055"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2023.110038"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.suronc.2016.05.027"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-020-02544-z"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-020-06954-7"},{"key":"e_1_2_8_7_1","volume-title":"TNM Classification of Malignant Tumours","author":"Brierley JD","year":"2017"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-198212000-00014"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9681(87)90171-8"},{"key":"e_1_2_8_10_1","unstructured":"EORTC QLQ\u2010C30: general cancer QoL questionnaire [September 2023]. Available at:https:\/\/qol.eortc.org\/questionnaire\/eortc\u2010qlq\u2010c30\/. Accessed 05 September 2023"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(01)00448-8"},{"key":"e_1_2_8_12_1","unstructured":"EORTC\u2010BLM30: muscle\u2010invasive QoL questionnaire [December 2023]. Available at:https:\/\/qol.eortc.org\/questionnaire\/qlq\u2010blm30\/. Accessed 10 December 2023"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12955-022-02064-z"},{"key":"e_1_2_8_14_1","volume-title":"The EORTC QLQ\u2010C30 Scoring Manual","author":"Fayers PMAN","year":"2001"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.3233\/BLC-210013"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-012-1680-8"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2012.02.059"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpr.2019.05.001"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2010.01.087"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyaa123"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2023.04.004"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12957-023-03132-4"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.6_suppl.489"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euf.2019.02.017"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/bju.15505"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2021.09.018"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/bju.16242"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2009.10.038"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2019.11.001"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2021.01.032"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2023.11.007"}],"container-title":["BJU International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bju.16736","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T13:08:25Z","timestamp":1761743305000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/10.1111\/bju.16736"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,16]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["10.1111\/bju.16736"],"URL":"https:\/\/doi.org\/10.1111\/bju.16736","archive":["Portico"],"relation":{},"ISSN":["1464-4096","1464-410X"],"issn-type":[{"value":"1464-4096","type":"print"},{"value":"1464-410X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,16]]},"assertion":[{"value":"2025-04-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}